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Background: Transcranial direct current stimulation (tDCS), a putative treatment for
depression, has been proposed to affect peripheral metabolism. Metabolic products from
brain tissue may also cross the blood–brain barrier, reflecting the conditions in the brain.
However, there are no previous data regarding the effect of tDCS on circulating metabolites.
Objective: To determine whether five daily sessions of tDCS modulate peripheral
metabolites in healthy adult men.
Methods: This double-blind, randomized controlled trial involved 79 healthy males (aged 20–
40 years) divided into two groups, one receiving tDCS (2 mA) and the other sham stimulated.
The anode was placed over the left dorsolateral prefrontal cortex and the cathode over the
corresponding contralateral area. Venous blood samples were obtained before and after the
first stimulation session, and after the fifth stimulation session. Serum levels of 102metabolites
were determined by mass spectrometry. The results were analysed with generalised
estimating equations corrected for the family-wise error rate. In addition, we performed
power calculations estimating sample sizes necessary for future research.
Results: TDCS-related variation in serum metabolite levels was extremely small and
statistically non-significant. Power calculations indicated that for the observed variation to
be deemed significant, samples sizes of up to 11,000 subjects per group would be
required, depending on the metabolite of interest.g May 2020 | Volume 11 | Article 4031
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Frontiers in Psychiatry | www.frontiersin.orConclusion: Our study found that five sessions of tDCS induced no major effects on
peripheral metabolites among healthy men. These observations support the view of tDCS
as a safe treatment that does not induce significant changes in the measured peripheral
metabolites in healthy male subjects.Keywords: brain stimulation, transcranial direct current stimulation, tES, metabolism, mass spectrometryINTRODUCTION
Transcranial direct current stimulation (tDCS) is a non-invasive
method for modulating neuronal activity by introducing a small
electric current into the brain via electrodes placed on the scalp. It
has attracted increasing interest among both clinicians and
researchers during the past decade. It has been speculated to be a
promising candidate in the treatment of major depressive disorder
(1), bipolar depression (2), dependence and craving (3), as well as
neuropathic and idiopathic pain (3). The low cost, safety and
simplicity of use make tDCS an attractive option for clinical
applications, even though more research is needed to determine
the optimal treatment protocols and patient characteristics.
At the cellular level, tDCS is considered to alter neuronal resting
membrane potentials (4, 5). For example, anodal stimulation has
been observed to lead to increased neuronal activity in the motor
cortex, while cathodal stimulation of the same area has been
considered to inhibit neuronal firing (5, 6). In addition to local
cortical effects in neuronal excitability, recent research has
demonstrated that tDCS also appears to exert changes in neuronal
activity in deeper brain structures, such as the midbrain nuclei (7).
The brain acts as a control unit that regulates the functions of
the entire organism, and is in turn modified by peripheral
physiology. Nevertheless, only limited knowledge is available on
possible peripheral changes induced by brain stimulation using
tDCS. Previous research has indicated that tDCS induces changes
in cerebral blood flow (8), brain neurotransmitter levels (9) and
central and peripheral metabolic activity (10). Furthermore,
anodal tDCS in the area corresponding to the left dorsolateral
prefrontal cortex (DLPFC) has been postulated to lead to changes
in autonomic nervous system activity, measured by high- and low-
frequency heart rate variability and the secretion of cortisol under
normal conditions (11), as well as in stressful situations (12, 13).
Thus, current evidence indicates that tDCS may induce very
specific physiological responses in both the central nervous
system and the periphery, although our understanding of
possible systemic metabolic adaptations is very limited.
Electrical fields created by tDCS exert force on polar and/or
charged molecules, and many proteins and amino acids, which
often serve as neurotransmitters of the brain, are charged. This
could lead to alterations in the concentrations of polar molecules
and trigger larger metabolic cascades. These consequences may
explain some of the observed physiological effects of tDCS in
both the central nervous system and the periphery.
With regards to the peripheral effects of tDCS, a previous study
conducted by Binkofski et al. (10) indicated that anodal tDCS led to
a transient drop in high-energy phosphorus compounds (adenosine
triphosphate (ATP), phosphocreatinine) both under the electrodeg 2and in the contralateral hemisphere, suggesting that there had been
a widespread increase in neuronal glutaminergic activity. By using a
hyperinsulinemic–euglycemic clamp, they also observed a
simultaneous increase in glucose uptake in the peripheral
circulation. The extent of the increase clearly correlated with the
levels of the previously mentioned energetic compounds in the
brain tissue, suggestive of elevated glucose uptake across the BBB.
As many physiological processes in the central nervous
system result in observable changes in metabolite profiles in
the periphery, metabolomic analysis of possible tDCS effects
could provide a valuable tool for investigating the safety profile
and mechanisms of action of tDCS. As many circulating
metabolites are biologically active compounds, alterations in
the levels of such compounds could result in safety concerns in
healthy or clinical populations. We investigated the acute effects
of tDCS on peripheral metabolites in a sample of 79 healthy men.
The working hypotheses were that the metabolic state of the
participants would change as a result of the stimulation and that
differences between the study groups could be reflected in altered
metabolite profiles.MATERIALS AND METHODS
Study Population
This investigation formed part of the larger Optimizing
Transcranial Electrical Stimulation for Clinical Applications
(OptES) Study. The OptES Study was designed to generate
novel information on the mechanisms of action of transcranial
electrical stimulation, and to use this information to develop
new, better clinical applications of transcranial electrical
stimulation. The study protocol was approved by the Ethics
Committee of the North Savo Hospital District (permit number
41/2015). All participants provided written informed consent
after a full explanation of the study. The study conformed with
the Declaration of Helsinki.
In order to decrease random variance in our findings, we
chose to include only male participants, since our metabolomics
platform also included some compounds known to be affected by
sex hormones either centrally (14) or in the periphery (15, 16). A
total of 80 male volunteers were recruited from the North Savo
region of Finland. The participants received either tDCS or sham
stimulation in a double-blind setting. The inclusion criteria were
male gender (to avoid possible confounding metabolic effects of
the menstrual cycle), aged between 18 and 40 years at the time of
recruitment, right-handedness (i.e., belonging to the 1st to 10th
right decile according to the Edinburgh Handedness
Questionnaire (17)), and not having previously received tDCS.May 2020 | Volume 11 | Article 403
Kortteenniemi et al. Peripheral Metabolic Changes of tDCSThe exclusion criteria were metal implants inside the skull or eye,
severe skin lesions in the electrode placement areas, a pacemaker,
a history of epilepsy or previous seizures, a history of
intracerebral bleeding during the previous six months, a self-
reported history of substance dependence/abuse during the past
six months and a history of any endocrinological condition [i.e.,
any physician-defined E00-E32 diagnosis according to the
International Statistical Classification of Diseases and Related
Health Problems version 10 (IDC-10) (18)]. We were unable to
obtain the post-stimulation venous blood sample from one
participant, and this individual was therefore excluded from all
analyses. Thus, the final sample size was 40 in the tDCS group
(mean age 28.3 years, mean BMI 26.0 kg/m2) and 39 in the sham
group (mean age 27.7 years, mean BMI 25.4 kg/m2).
Experimental Procedure
The participants were randomly assigned to either 1) the active
stimulation or 2) the sham stimulation group in a 1:1 fashion,
utilizing a computer-generated scheme. Basic sociodemographic
information, including age, height and weight used to calculate
the body mass index (BMI, kg/m2), was collected from
questionnaires that the participants completed prior to the first
stimulation. Three venous blood samples were collected via
venipuncture by a trained nurse.
Each participant received either tDCS or sham stimulation once
per day for five consecutive days (Figure 1). Sociodemographic
questionnaires were completed before the stimulation on day one.
The baseline blood sample was collected immediately before the
first stimulation session, with the second sample being drawn
immediately after the first stimulation session (in order to
investigate the acute effects of stimulation); the third sample was
drawn immediately after the fifth stimulation session. A maximum
of 5 min was allowed between stimulation and the collection of the
blood samples.
Before the experiment, the participants were instructed to
abstain from alcohol for 12 h and to have consumed no more
than two doses during the preceding 24 h, to abstain from
products containing caffeine for 3 h, and to abstain from
smoking and heavy exercise for 1 h prior to the experiment. In
addition, all experiments were conducted in the morning, and the
participants were instructed to fast for 10 h to allow fasting blood
samples to be obtained. This procedure enabled minimization of
the confounding metabolic effects of the consumption of dietary
products. Before stimulation, participant compliance with the
instructions was checked, and those not conforming to the
instructions were re-scheduled to another testing day.
Each participant received a 20-minute stimulation session with
a current of 2 mA using a neuroConn DC-Stimulator (neuroConn
GmbH, Ilmenau, Germany). The experimenter was unaware of
the form of stimulation delivered (i.e., active stimulation vs. sham
stimulation), and the participants were randomly divided between
the study groups by a computer. The electrodes were made of
conductive rubber placed inside sponge pads soaked with 12 ml of
saline and held down with elastic straps. The electrode area was
25 cm2, resulting in a current density of 0.8 A/m2. The anode was
placed at site F3 and the cathode at site F4 according to the
international 10–20 electroencephalography system. In order toFrontiers in Psychiatry | www.frontiersin.org 3standardize the external stimuli, during the stimulation the
participants were asked to refrain from talking and to watch a
neutral landscape video with headphones on. The sham group
received 15 seconds of ramping up and ramping down at the
beginning, after which stimulation was discontinued.
After the stimulation, both the participant and the
experimenter filled in a form in which they were asked to
provide their estimate (percentage) of the likelihood of the
participant belonging to the sham group.
Blood Sample Analysis
Venous blood samples were collected into Vacuette 454078 4-ml
serum gel tubes (Greiner Bio-One GmbH, Rainbach im
Mühlkreis, Austria). They were left at room temperature for 30
min, followed by 10 min of centrifugation at 2,400×g, +20°C, to
separate serum. The serum samples were frozen at −80°C until
analysed. The metabolites were extracted from the serum samples
using acetonitrile:formic acid (99:1 v/v) as a solvent (1:4, sample:
solvent) and analysed using an ACQUITY UPLC-MS/MS system
(Waters Corporation, Milford, MA, USA). A detailed protocol
and instrument conditions have been published elsewhere (19).FIGURE 1 | Timeline of the study.May 2020 | Volume 11 | Article 403
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Preliminary inspections of the metabolomic data allowed the
detection of a total of 2,124 missing observations (8.786% of the
values in the dataset). Because an excessive number of missing
values for some of the measured compounds could potentially
introduce unanticipated biases, metabolites with ≥50% of missing
values within either of the experimental groups (n = 9) were
excluded from any further statistical testing (Supplementary
Table 1, Supplementary Figure 1), and the remaining
metabolites (n = 93) were included in the further analyses.
After appropriate transformation and baseline standardization,
each metabolite was subsequently entered into a generalized
estimating equations model to investigate differences between
groups in their respective values at baseline and after tDCS or
sham stimulations were applied. The p-value threshold for
statistical significance was set at p ≤5.376e−04, as the complexity of
the analyses developed required accounting for both the family-wise
error rate (Bonferroni method) and the intrinsic correlated nature of
themetabolite data. Further details of themodels implemented can be
found in the Supplementary Methods and Supplementary Figure 2
These main statistical analyses were subsequently supplemented
with a set of power-related computations utilizing statistical
simulations within a sophisticated computer cluster environment.
Firstly, we evaluated the sensitivity obtained with the current
sample in its ability to detect significant longitudinal differences
between groups with ≥80% power (for 0.05 and 5.376e−04 type-I
error rates). This would allow an estimation of the minimum level
of detection with the current experimental set-up. Subsequently, for
each metabolite, we evaluated the sample size that would be
required to detect the variation in metabolites caused by tDCS in
this study as statistically significant with ≥80% power (type-I error
rates 0.05 and 5.376e−04). This was done in order to make an
estimate of the sample size needed in future experimental settings
aiming to detect similar changes in metabolites resulting from
tDCS (assuming that the detected values in this experiment would
apply to other healthy populations with similar characteristics).
Further details of these computations are offered in the
Supplementary Methods.
Lastly, the success of the blinding procedure was investigated by
running a set of Mann–Whitney U-tests for both the participants
and the experimenters on days one and five. They were asked how
likely they thought it was, as a percentage, that they were part of
the sham group, and the answers were used in the analysis.RESULTS
The current double-blind, randomized controlled trial failed to
detect any metabolic changes due to tDCS after five treatment
sessions; none of the models implemented for any of the
investigated metabolites displayed statistically significant
coefficients. Figure 2 presents the model coefficients obtained
for each metabolite, while the specific values provided by the
statistical tests can be found in Table 1.
The computations related to statistical power made it possible
to draw relevant conclusions concerning the usability of theFrontiers in Psychiatry | www.frontiersin.org 4current data. Firstly, the conducted analyses suggested that our
study sample conferred enough power (80% level) to detect
relatively small differences between groups due to tDCS (an
absolute value for the “Time x Group” model coefficient of
≥0.1493 would be detectable with a type-I error rate of 5.376 ·
10−4). However, the majority of the tDCS effects observed here
were substantially smaller than that threshold, and only a single
metabolite, 2-aminoisobutyric acid, surpassed it. However, this
metabolite was not ultimately considered as significant, because
the model estimates displayed high uncertainties (for instance,
see the extremely large standard error for the corresponding
coefficients in Table 1).
Secondly, future replication studies aiming to detect
significant group differences due to tDCS will need to increase
their sample size considerably, as the treatment effects detected
in our data were extremely small. For example, increasing the
sample size to n = 150 participants per group (i.e., n = 300 in
total) would have made it possible to identify six metabolites as
displaying statistically significant differences between the study
groups: 2-aminoisobutyric acid and propionylcarnitine being
upregulated and hippuric acid, L-glutamine, xanthine and
gamma-aminobutyric acid being downregulated in the tDCS
group. Figures 3 and 4 provide more details on this sample
size estimation. Detailed results from the calculations are
available in Supplementary Table 2.
Finally, it should be acknowledged here that the blinding
protocol was not totally successful, as a larger number of
participants and experimenters on day 1 compared to day 5
successfully guessed that they belonged to the sham group (p =
0.041 for participants, 0.012 for experimenters).DISCUSSION
This investigation revealed that five daily sessions of tDCS
applied to healthy male adults exerted no significant impact on
serum metabolite levels when compared to sham stimulation.
Although our study was adequately powered to detect relatively
small effect sizes (more specifically, ≥0.1493), tDCS produced
either no or extremely small effects for the majority of the
metabolites evaluated. This study further demonstrated that in
order to detect the observed minuscule effects as statistically
significant, the sample sizes would need to be extremely large,
making such a hypothetical study unfeasible.
In principle, tDCS could affect peripheral metabolite levels via
two mechanisms: either indirectly through changes in the central
nervous system that would modify peripheral neural responses
and consequently peripheral metabolism, or directly through
central metabolites passing through the BBB. While tDCS does
not appear to lead to long-lasting changes in BBB permeability
(20), short-lasting functional changes in its permeability could
evoke changes in metabolite levels in the peripheral circulation.
Our findings did not support a clinically significant presence of
such changes, and the above hypotheses remain to be further
tested in animal or human models.
Peripheral metabolic effects and serum effects caused by tDCS
have previously been investigated in a limited number ofMay 2020 | Volume 11 | Article 403
Kortteenniemi et al. Peripheral Metabolic Changes of tDCSstudies.(10–13, 21–23) In these studies, one session of tDCS was
found to cause changes in glucose metabolism (10, 21) and
cortisol secretion (11–13, 23) when investigating healthy
individuals. The sample sizes of the glucose studies were 15
(sham-controlled cross-over design), and 9 (within-subjects
design, no sham, measurements before and after stimulation),
respectively, while the sample sizes of the cortisol studies ranged
from 20 to 60. Interestingly, one of the studies indicated that theFrontiers in Psychiatry | www.frontiersin.org 5hormone-related effect of tDCS varies based on pre-existing
conditions. Subjects with high math anxiety experienced
reduced serum cortisol with tDCS compared to sham
stimulation, while receiving tDCS was associated with no
change in serum cortisol in subjects with low math anxiety (13).
In addition, Khedr et al. (22), in a study with 40 participants,
observed that 10 consecutive sessions of tDCS lowered pain, a
finding that correlated with an increase in serum endorphin levelsFIGURE 2 | Coefficient values with 95% confidence intervals from each metabolite model analysis.May 2020 | Volume 11 | Article 403
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6Metabolite Name Baseline Post session 1 Post session 5 Coefficient for
“Time” **
tDCS Group * Sham Group * tDCS Group * Sham Group * tDCS Group * Sham Group *
2-Aminoadipic acid 39; 0.012 (0.166) 39; −0.012 (0.156) 40; 0.092 (0.153) 39; 0.062 (0.177) 39; 0.228 (0.136) 39; −0.106 (0.151) −0.018 (0.027); 0.434; 0.51
2-Aminoisobutyric acid 40; 0.127 (0.129) 39; −0.13 (0.185) 40; 0.137 (0.131) 39; −0.065 (0.18) 40; 0.283 (0.141) 39; 0.217 (0.156) 0.092 (0.726); 0.016; 0.899
3-Hydroxyanthranilic acid 40; 0.055 (0.151) 39; −0.056 (0.169) 40; −0.051 (0.128) 39; −0.139 (0.168) 40; −0.082 (0.153) 39; −0.092 (0.143) −0.011 (0.025); 0.206; 0.65
4-Pyridoxic acid 40; −0.044 (0.121) 39; 0.045 (0.192) 40; -0.067 (0.118) 39; 0.034 (0.186) 40; −0.05 (0.16) 39; 0.214 (0.19) 0.037 (0.019); 3.726; 0.054
Acetoacetic acid 40; 0.005 (0.154) 39; −0.005 (0.167) 40; −0.044 (0.158) 39; −0.193 (0.174) 40; −0.223 (0.18) 39; −0.148 (0.163) −0.012 (0.018); 0.413; 0.52
Adenine 40; −0.021 (0.176) 39; 0.022 (0.142) 40; −0.174 (0.132) 39; 0.007 (0.195) 40; 0.04 (0.135) 39; −0.044 (0.134) −0.012 (0.027); 0.205; 0.651
Adenosine 40; −0.066 (0.164) 39; 0.067 (0.155) 40; 0.252 (0.163) 39; 0.225 (0.177) 40; 0.057 (0.186) 39; 0.378 (0.167) 0.054 (0.024); 4.931; 0.026
Adenosine
monophosphate
40; 0.04 (0.142) 39; −0.041 (0.177) 40; 0.101 (0.138) 39; 0.349 (0.145) 40; 0.251 (0.123) 39; 0.211 (0.14) 0.044 (0.027); 2.721; 0.099
Allantoin 40; 0.038 (0.173) 39; −0.039 (0.144) 40; −0.125 (0.174) 39; −0.103 (0.154) 40; −0.312 (0.177) 39; −0.177 (0.154) −0.017 (0.025); 0.439; 0.507
alpha-D-glucuronic acid 40; −0.016 (0.165) 39; 0.016 (0.155) 40; −0.176 (0.158) 39; −0.071 (0.172) 40; −0.054 (0.15) 39; −0.132 (0.142) -0.028 (0.021); 1.87; 0.172
Asymmetric
dimethylarginine
40; −0.145 (0.16) 39; 0.149 (0.157) 40; 0.171 (0.135) 39; 0.062 (0.134) 40; 0.034 (0.132) 39; 0.236 (0.154) 0.022 (0.041); 0.282; 0.595
Betaine 40; 0.008 (0.16) 39; −0.008 (0.16) 40; −0.083 (0.153) 39; 0.048 (0.133) 40; 0.01 (0.176) 39; 0.003 (0.119) 0.005 (0.027); 0.036; 0.85
Carnosine 40; 0.114 (0.153) 39; −0.116 (0.165) 40; 0.05 (0.143) 39; 0.061 (0.134) 40; 0.064 (0.129) 39; −0.004 (0.115) 0.021 (0.025); 0.752; 0.386
Chenodeoxycholic acid 40; 0.046 (0.143) 39; −0.047 (0.176) 40; 0.026 (0.138) 39; −0.14 (0.167) 40; −0.286 (0.123) 39; −0.133 (0.186) −0.013 (0.023); 0.321; 0.571
Cholic acid 30; 0.08 (0.186) 28; −0.086 (0.188) 26; −0.159 (0.209) 25; −0.175 (0.161) 27; 0.002 (0.194) 23; −0.387 (0.202) −0.018 (0.047); 0.151; 0.697
Choline 40; 0.03 (0.148) 39; −0.031 (0.171) 40; −0.024 (0.175) 39; −0.044 (0.157) 40; −0.121 (0.158) 39; 0.05 (0.197) 0.019 (0.036); 0.287; 0.592
Citrulline 40; 0.035 (0.166) 39; −0.036 (0.154) 40; −0.127 (0.152) 39; −0.163 (0.151) 40; −0.229 (0.182) 39; −0.164 (0.18) −0.014 (0.026); 0.284; 0.594
Creatine 40; 0.302 (0.151) 39; −0.309 (0.154) 40; 0.308 (0.146) 39; −0.074 (0.133) 40; 0.229 (0.141) 39; −0.051 (0.137) 0.057 (0.019); 8.719; 0.003
Creatinine 40; −0.087 (0.154) 39; 0.089 (0.165) 40; −0.098 (0.149) 39; −0.024 (0.157) 40; −0.026 (0.164) 39; 0.076 (0.176) 0.005 (0.015); 0.098; 0.754
Cyclic AMP 40; 0.129 (0.174) 39; −0.133 (0.141) 40; 0.086 (0.141) 39; −0.054 (0.14) 40; 0.043 (0.135) 39; 0.021 (0.141) 0.02 (0.023); 0.77; 0.38
Cytidine 40; 0.038 (0.14) 39; −0.039 (0.179) 40; −0.013 (0.133) 39; −0.054 (0.177) 40; −0.045 (0.167) 39; 0.066 (0.195) 0.016 (0.035); 0.207; 0.649
Cytosine 40; −0.013 (0.18) 39; 0.013 (0.137) 40; −0.079 (0.16) 39; 0.015 (0.139) 40; −0.304 (0.16) 39; −0.232 (0.14) −0.04 (0.026); 2.348; 0.125
D-Ribose-5-phosphate 40; 0.053 (0.162) 39; −0.054 (0.157) 40; 0.038 (0.147) 39; 0.02 (0.144) 40; 0.129 (0.128) 39; −0.023 (0.14) 0.02 (0.027); 0.555; 0.456
Decanoylcarnitine 40; 0.04 (0.156) 39; −0.041 (0.165) 40; −0.105 (0.18) 39; −0.401 (0.18) 40; −0.36 (0.173) 39; −0.287 (0.112) 0.005 (0.039); 0.015; 0.902
Deoxycytidine 40; 0.018 (0.128) 39; −0.018 (0.188) 40; −0.036 (0.123) 39; −0.127 (0.184) 40; −0.267 (0.136) 39; −0.044 (0.177) −0.01 (0.014); 0.528; 0.468
Deoxyuridine 40; −0.02 (0.151) 39; 0.02 (0.169) 40; 0.058 (0.153) 39; −0.025 (0.17) 40; 0.031 (0.139) 39; 0.121 (0.189) 0.026 (0.02); 1.6; 0.206
Dimethylglycine 40; −0.106 (0.145) 39; 0.109 (0.173) 40; −0.129 (0.145) 39; -0.007 (0.162) 40; −0.089 (0.13) 39; 0.112 (0.169) −0.061 (0.031); 3.848; 0.05
Folic acid 40; 0.063 (0.175) 39; −0.064 (0.142) 40; 0.181 (0.16) 39; 0.016 (0.134) 40; −0.053 (0.184) 39; −0.169 (0.148) −0.034 (0.026); 1.706; 0.191
Gamma-Aminobutyric
acid
40; −0.116 (0.163) 39; 0.119 (0.155) 40; 0.004 (0.155) 39; −0.102 (0.149) 40; 0.184 (0.148) 39; −0.18 (0.129) −0.05 (0.032); 2.479; 0.115
Gamma-Glutamylcysteine 38; −0.05 (0.169) 34; 0.055 (0.165) 37; −0.205 (0.133) 38; 0.035 (0.175) 38; 0.014 (0.159) 34; −0.005 (0.145) −0.014 (0.019); 0.505; 0.477
Glyceraldehyde 40; 0.167 (0.143) 39; −0.171 (0.172) 40; −0.089 (0.135) 39; −0.271 (0.163) 40; 0.089 (0.139) 39; −0.243 (0.154) −0.007 (0.029); 0.064; 0.8
Glycine 40; −0.296 (0.169) 39; 0.304 (0.133) 40; −0.319 (0.177) 39; 0.36 (0.143) 40; −0.304 (0.183) 39; 0.094 (0.125) −0.039 (0.018); 4.72; 0.03
Glycocholic acid 40; 0.011 (0.165) 39; −0.012 (0.155) 40; −0.31 (0.172) 39; −0.465 (0.164) 40; −0.61 (0.163) 39; −0.467 (0.153) −0.092 (0.036); 6.521; 0.011
Guanidoacetic acid 40; 0.028 (0.149) 39; −0.029 (0.171) 40; −0.159 (0.144) 39; −0.209 (0.169) 40; 0.005 (0.2) 39; −0.216 (0.187) −0.021 (0.023); 0.838; 0.36
Guanosine 40; −0.068 (0.159) 39; 0.07 (0.16) 40; 0.179 (0.133) 39; 0.023 (0.161) 40; −0.064 (0.137) 39; 0.06 (0.161) 0 (0.022); 0; 0.994
Hexanoylcarnitine 40; 0.133 (0.162) 39; −0.136 (0.155) 40; −0.165 (0.161) 39; −0.496 (0.165) 40; −0.251 (0.177) 39; −0.45 (0.127) −0.067 (0.031); 4.866; 0.027
Hippuric acid 40; −0.254 (0.145) 39; 0.261 (0.164) 40; −0.451 (0.135) 39; 0.039 (0.159) 40; 0.003 (0.192) 39; 0.116 (0.167) −0.029 (0.034); 0.718; 0.397
Homocysteine 40; -0.08 (0.15) 39; 0.082 (0.169) 40; −0.094 (0.156) 39; 0.088 (0.168) 40; −0.118 (0.146) 39; 0.125 (0.158) 0.017 (0.035); 0.235; 0.628
Homogentisic acid 40; 0.144 (0.165) 39; −0.147 (0.151) 40; −0.06 (0.135) 38; −0.261 (0.183) 40; −0.131 (0.131) 39; −0.102 (0.137) 0.02 (0.022); 0.865; 0.352
Hydroxykynurenine 40; 0.053 (0.158) 39; −0.055 (0.161) 40; −0.004 (0.128) 39; −0.043 (0.171) 40; −0.092 (0.154) 39; 0.143 (0.156) 0.038 (0.025); 2.291; 0.13
Hypoxanthine 40; 0.135 (0.155) 39; −0.138 (0.163) 40; −0.129 (0.117) 39; −0.02 (0.141) 40; 0.041 (0.131) 39; −0.181 (0.119) −0.005 (0.033); 0.022; 0.883
Inosine 40; −0.109 (0.159) 39; 0.112 (0.159) 40; 0.154 (0.12) 39; 0.083 (0.155) 40; 0.062 (0.148) 39; 0.055 (0.16) −0.011 (0.028); 0.155; 0.694
Inosinic acid 40; 0.008 (0.17) 39; −0.008 (0.149) 40; −0.085 (0.171) 39; 0.136 (0.161) 40; −0.113 (0.174) 39; −0.159 (0.159) −0.046 (0.022); 4.373; 0.037
Isobutyryl-L-carnitine 40; −0.09 (0.145) 39; 0.092 (0.174) 40; −0.285 (0.134) 39; −0.131 (0.165) 40; −0.555 (0.139) 39; −0.192 (0.175) −0.067 (0.022); 9.072; 0.003
Isovalerylcarnitine 40; 0.035 (0.134) 39; −0.035 (0.183) 40; −0.001 (0.128) 39; −0.214 (0.176) 40; −0.385 (0.145) 39; −0.147 (0.154) −0.025 (0.03); 0.698; 0.403
Kynurenic acid 40; 0.057 (0.137) 39; −0.059 (0.181) 40; −0.065 (0.133) 39; −0.23 (0.167) 40; 0.118 (0.155) 39; −0.066 (0.175) 0.013 (0.027); 0.236; 0.627
L-Acetylcarnitine 40; 0.049 (0.154) 39; −0.05 (0.166) 40; −0.027 (0.171) 39; −0.111 (0.168) 40; 0.044 (0.2) 39; −0.009 (0.16) 0.004 (0.044); 0.007; 0.931




“Time × Group” **
.001 −0.262 (0.23); 1.298; 0.255 0.029 (0.039); 0.569; 0.451
35 0.025 (0.226); 0.012; 0.912 0.016 (0.03); 0.277; 0.599
61 −0.17 (0.226); 0.564; 0.453 0.046 (0.032); 2.072; 0.15
227 0.065 (0.219); 0.087; 0.767 0.025 (0.051); 0.241; 0.624
54 −0.113 (0.227); 0.248; 0.618 −0.049 (0.02); 5.801; 0.016
242 −0.384 (0.22); 3.037; 0.081 −0.039 (0.035); 1.229; 0.268
53 0.292 (0.218); 1.788; 0.181 −0.047 (0.036); 1.776; 0.183
344 −0.353 (0.473); 0.558; 0.455 0.088 (0.121); 0.53; 0.467
96 −0.009 (0.221); 0.002; 0.968 0.004 (0.035); 0.015; 0.903
; 0 −0.081 (0.201); 0.161; 0.688 0.072 (0.047); 2.341; 0.126
59 0.048 (0.223); 0.047; 0.828 −0.02 (0.027); 0.516; 0.473
74 −0.255 (0.221); 1.33; 0.249 0.024 (0.043); 0.307; 0.58
11 0.117 (0.226); 0.266; 0.606 −0.03 (0.028); 1.136; 0.286
32 0.349 (0.226); 2.375; 0.123 −0.053 (0.042); 1.572; 0.21
076 −0.037 (0.227); 0.027; 0.87 0.012 (0.035); 0.118; 0.731
717 0.095 (0.226); 0.176; 0.675 −0.037 (0.043); 0.768; 0.381
809 0.032 (0.23); 0.019; 0.889 −0.019 (0.031); 0.373; 0.541
.001 0.088 (0.228); 0.15; 0.698 0.013 (0.03); 0.194; 0.66
33 0.33 (0.228); 2.091; 0.148 −0.05 (0.041); 1.504; 0.22
53 −0.136 (0.226); 0.363; 0.547 −0.016 (0.033); 0.23; 0.632
.002 −0.022 (0.221); 0.01; 0.922 0.026 (0.042); 0.375; 0.54
007 −0.083 (0.228); 0.134; 0.714 0.036 (0.038); 0.871; 0.351
073 0.035 (0.23); 0.023; 0.879 −0.045 (0.028); 2.544; 0.111
88 0.312 (0.225); 1.926; 0.165 −0.04 (0.037); 1.185; 0.276
61 −0.133 (0.227); 0.345; 0.557 0.031 (0.043); 0.517; 0.472
788 −0.349 (0.214); 2.66; 0.103 0.032 (0.023); 1.863; 0.172
441 −0.222 (0.205); 1.178; 0.278 0.015 (0.042); 0.134; 0.714
33 0.463 (0.226); 4.194; 0.041 −0.003 (0.052); 0.003; 0.958
05 0.026 (0.221); 0.013; 0.908 −0.032 (0.039); 0.672; 0.412
23 −0.072 (0.198); 0.133; 0.716 −0.029 (0.041); 0.508; 0.476
809 −0.117 (0.228); 0.264; 0.607 0.019 (0.039); 0.237; 0.626
419 0.029 (0.227); 0.016; 0.899 0.023 (0.033); 0.499; 0.48
117 0.09 (0.231); 0.153; 0.696 −0.085 (0.026); 10.381; 0.001
062 −0.095 (0.228); 0.173; 0.677 0.036 (0.037); 0.962; 0.327
04 −0.441 (0.229); 3.722; 0.054 0.045 (0.035); 1.636; 0.201
93 −0.038 (0.218); 0.03; 0.863 −0.014 (0.032); 0.198; 0.656
82 0.029 (0.206); 0.02; 0.889 0.004 (0.03); 0.021; 0.885
44 −0.481 (0.22); 4.752; 0.029 0.06 (0.04); 2.222; 0.136
2 0.126 (0.218); 0.334; 0.563 −0.039 (0.052); 0.575; 0.448
1 0.187 (0.223); 0.705; 0.401 −0.059 (0.042); 1.97; 0.16
694 0.064 (0.224); 0.083; 0.773 0.005 (0.047); 0.01; 0.919
03 0.006 (0.233); 0.001; 0.979 −0.032 (0.043); 0.555; 0.456
56 −0.019 (0.223); 0.007; 0.931 −0.037 (0.038); 0.934; 0.334
321 0.058 (0.202); 0.083; 0.773 0.03 (0.044); 0.482; 0.488
89 0.065 (0.212); 0.095; 0.758 0.103 (0.042); 5.941; 0.015
893 0.227 (0.209); 1.183; 0.277 −0.001 (0.044); 0; 0.989

































7Metabolite Name Baseline Post session 1 Post session 5 Coefficient for
“Time” **
tDCS Group * Sham Group * tDCS Group * Sham Group * tDCS Group * Sham Group *
L-Alanine 40; −0.119 (0.166) 39; 0.122 (0.151) 40; −0.152 (0.184) 39; 0.02 (0.142) 40; −0.485 (0.168) 39; −0.373 (0.149) −0.093 (0.028); 10.741; 0
L-Arginine 40; 0.023 (0.153) 39; −0.024 (0.167) 40; 0.054 (0.149) 39; −0.008 (0.151) 40; 0.225 (0.148) 39; 0.097 (0.172) 0.022 (0.019); 1.408; 0.
L-Asparagine 40; −0.08 (0.166) 39; 0.082 (0.152) 40; −0.129 (0.181) 39; 0.023 (0.155) 40; 0.13 (0.167) 39; 0.092 (0.161) 0.013 (0.025); 0.261; 0
L-Aspartic acid 40; 0.107 (0.165) 39; −0.109 (0.153) 40; −0.375 (0.143) 39; −0.205 (0.163) 40; −0.091 (0.175) 39; −0.333 (0.157) −0.038 (0.031); 1.457; 0
L-Carnitine 40; −0.027 (0.16) 39; 0.028 (0.16) 40; −0.065 (0.163) 39; 0.059 (0.154) 40; −0.128 (0.17) 39; 0.159 (0.154) 0.026 (0.014); 3.701; 0.
L-Cystathionine 40; -0.184 (0.13) 39; 0.189 (0.181) 40; −0.378 (0.122) 39; 0.058 (0.187) 40; −0.457 (0.117) 39; 0.09 (0.175) −0.027 (0.023); 1.368; 0
L-Glutamic acid 40; 0.159 (0.171) 39; −0.163 (0.143) 40; 0.062 (0.136) 39; −0.033 (0.152) 40; 0.053 (0.126) 39; −0.198 (0.131) 0.017 (0.022); 0.564; 0.
L-Glutamine 40; −0.089 (0.15) 39; 0.091 (0.169) 40; −0.04 (0.148) 39; 0.136 (0.17) 40; 0.064 (0.136) 39; 0.095 (0.153) −0.083 (0.088); 0.896; 0
L-Histidine 40; 0.006 (0.161) 39; −0.006 (0.159) 40; 0.013 (0.144) 39; −0.036 (0.16) 40; 0.155 (0.164) 39; 0.104 (0.176) 0.026 (0.025); 1.094; 0.
L-Homoserine 40; −0.017 (0.167) 39; 0.017 (0.152) 40; −0.243 (0.156) 39; −0.11 (0.145) 40; −0.319 (0.155) 39; −0.604 (0.148) −0.116 (0.028); 17.574
L-Isoleucine 40; 0.043 (0.161) 39; −0.044 (0.158) 40; −0.162 (0.133) 39; −0.154 (0.171) 40; −0.13 (0.144) 39; −0.122 (0.155) −0.008 (0.014); 0.29; 0
L-Kynurenine 40; −0.082 (0.148) 39; 0.084 (0.171) 40; −0.128 (0.138) 39; 0.101 (0.163) 40; 0.159 (0.159) 39; 0.252 (0.191) 0.035 (0.032); 1.198; 0.
L-Leucine 40; 0.051 (0.151) 39; −0.052 (0.169) 40; −0.102 (0.167) 39; −0.24 (0.161) 40; 0.05 (0.169) 39; 0.049 (0.188) 0.042 (0.016); 6.525; 0.
L-Lysine 40; 0.184 (0.152) 39; −0.188 (0.163) 40; 0.266 (0.162) 39; −0.151 (0.159) 40; 0.236 (0.159) 39; 0.061 (0.202) 0.062 (0.029); 4.611; 0.
L-Methionine 40; 0.015 (0.154) 39; −0.016 (0.166) 40; −0.182 (0.151) 39; −0.086 (0.169) 40; −0.103 (0.16) 39; −0.224 (0.148) −0.039 (0.022); 3.154; 0
L-Octanoylcarnitine 40; 0.049 (0.162) 39; −0.05 (0.158) 40; −0.032 (0.187) 39; −0.292 (0.163) 40; −0.236 (0.179) 39; −0.237 (0.115) −0.012 (0.033); 0.131; 0
L-Ornithine 40; 0.051 (0.161) 39; −0.052 (0.158) 40; −0.152 (0.167) 39; −0.094 (0.168) 40; −0.161 (0.169) 39; −0.086 (0.155) −0.005 (0.019); 0.059; 0
L-Phenylalanine 40; 0.061 (0.167) 39; −0.062 (0.151) 40; −0.129 (0.145) 39; −0.225 (0.145) 40; 0.011 (0.153) 39; −0.201 (0.14) −0.046 (0.014); 10.562; 0
L-Proline 40; 0.162 (0.171) 39; −0.166 (0.143) 40; 0.06 (0.169) 39; −0.163 (0.132) 40; −0.212 (0.186) 39; −0.355 (0.153) −0.03 (0.031); 0.936; 0.
L-Serine 40; −0.006 (0.129) 39; 0.006 (0.188) 40; −0.056 (0.127) 39; 0.168 (0.194) 40; 0.093 (0.145) 39; 0.233 (0.18) 0.037 (0.026); 2.04; 0.1
L-Threonine 40; 0.004 (0.149) 39; −0.004 (0.171) 40; −0.098 (0.143) 39; −0.047 (0.169) 40; −0.241 (0.189) 39; −0.443 (0.137) −0.081 (0.026); 10.062; 0
L-Tryptophan 40; −0.009 (0.138) 39; 0.009 (0.18) 40; −0.272 (0.145) 39; −0.262 (0.174) 40; −0.179 (0.154) 39; −0.298 (0.151) −0.078 (0.029); 7.173; 0
L-Tyrosine 40; 0.035 (0.153) 39; −0.036 (0.167) 40; −0.225 (0.16) 39; −0.226 (0.162) 40; −0.323 (0.155) 39; −0.216 (0.187) −0.032 (0.018); 3.203; 0
L-Valine 40; 0.148 (0.138) 39; −0.152 (0.177) 40; −0.008 (0.145) 39; −0.282 (0.164) 40; 0.025 (0.168) 39; −0.096 (0.169) 0.022 (0.025); 0.745; 0.
Myo-inositol 40; −0.009 (0.156) 39; 0.01 (0.164) 40; −0.171 (0.142) 39; 0.024 (0.196) 40; 0.181 (0.16) 39; 0.09 (0.163) 0.024 (0.027); 0.833; 0.
N(tele)-methylhistamine 40; −0.108 (0.158) 39; 0.111 (0.161) 40; −0.047 (0.148) 39; 0.175 (0.15) 40; 0.016 (0.152) 39; 0.094 (0.162) −0.004 (0.013); 0.072; 0
NAD 40; −0.08 (0.168) 39; 0.082 (0.15) 40; −0.056 (0.135) 39; 0.135 (0.177) 40; −0.08 (0.133) 39; 0.022 (0.156) −0.019 (0.025); 0.593; 0
Niacinamide 40; 0.23 (0.143) 39; −0.236 (0.168) 40; 0.929 (0.189) 39; 0.394 (0.147) 40; 0.377 (0.162) 39; −0.08 (0.175) 0.045 (0.037); 1.425; 0.
Normetanephrine 40; 0.053 (0.176) 39; −0.054 (0.142) 40; 0.287 (0.145) 39; 0.376 (0.177) 40; 0.22 (0.144) 39; 0.301 (0.148) 0.065 (0.023); 7.89; 0.0
O-Phosphoethanolamine 40; 0.002 (0.136) 39; −0.002 (0.182) 40; −0.053 (0.138) 39; 0.079 (0.122) 40; −0.049 (0.143) 39; 0.075 (0.15) 0.018 (0.036); 0.242; 0.
Orotic acid 40; 0.087 (0.155) 39; −0.089 (0.164) 40; −0.139 (0.187) 39; 0.256 (0.219) 40; 0.026 (0.158) 39; 0.045 (0.161) −0.007 (0.029); 0.058; 0
Pantothenic acid 40; 0.058 (0.153) 39; −0.059 (0.166) 40; −0.074 (0.151) 39; −0.054 (0.191) 40; 0.011 (0.157) 39; −0.123 (0.193) −0.018 (0.023); 0.652; 0
Propionylcarnitine 40; 0.051 (0.138) 39; −0.052 (0.18) 40; −0.168 (0.141) 39; −0.235 (0.174) 40; −0.404 (0.142) 39; −0.103 (0.18) −0.027 (0.017); 2.461; 0
Sorbitol 40; −0.02 (0.184) 39; 0.02 (0.13) 40; −0.199 (0.187) 39; −0.012 (0.133) 40; 0.028 (0.188) 39; −0.174 (0.142) −0.032 (0.017); 3.476; 0
Spermidine 40; −0.156 (0.173) 39; 0.16 (0.14) 40; −0.033 (0.171) 39; 0.47 (0.181) 40; 0.378 (0.191) 39; 0.562 (0.162) 0.069 (0.024); 8.464; 0.
Succinic acid 40; −0.057 (0.157) 39; 0.058 (0.163) 40; −0.282 (0.158) 39; −0.253 (0.152) 40; −0.27 (0.141) 39; −0.121 (0.171) −0.015 (0.022); 0.47; 0.
Sucrose 40; 0.054 (0.156) 39; −0.056 (0.164) 40; −0.049 (0.16) 39; 0.088 (0.134) 40; 0.068 (0.147) 39; −0.039 (0.144) 0.003 (0.02); 0.022; 0.8
Symmetric
dimethylarginine
40; −0.224 (0.161) 39; 0.23 (0.15) 40; −0.169 (0.154) 39; 0.113 (0.148) 40; 0.201 (0.154) 39; 0.378 (0.134) 0.037 (0.026); 2.134; 0.
Taurine 40; 0.102 (0.158) 39; −0.104 (0.16) 40; −0.285 (0.138) 39; −0.114 (0.155) 40; −0.057 (0.161) 39; −0.079 (0.159) 0.014 (0.04); 0.129; 0.
Taurochenodesoxycholic
acid
40; 0.057 (0.171) 39; −0.059 (0.147) 40; −0.222 (0.158) 39; −0.401 (0.129) 40; −0.487 (0.131) 39; −0.332 (0.145) −0.078 (0.03); 6.61; 0.
Taurocholic acid 40; 0.02 (0.138) 39; −0.021 (0.18) 40; −0.064 (0.138) 39; −0.152 (0.17) 40; 0.011 (0.16) 39; −0.047 (0.186) −0.014 (0.035); 0.155; 0
trans-4-Hydroxy-L-proline 40; 0.012 (0.165) 39; −0.012 (0.154) 40; 0.01 (0.163) 39; 0.007 (0.152) 40; −0.301 (0.159) 39; −0.166 (0.165) 0.008 (0.033); 0.062; 0.
Trimethylamine N-oxide 40; −0.046 (0.144) 39; 0.047 (0.175) 40; −0.058 (0.139) 39; 0.099 (0.181) 40; −0.131 (0.147) 39; 0.043 (0.178) 0.018 (0.03); 0.347; 0.5
Uracil 40; 0.038 (0.177) 39; −0.039 (0.141) 40; −0.165 (0.176) 39; −0.158 (0.154) 40; −0.011 (0.134) 39; −0.235 (0.155) −0.031 (0.031); 0.986; 0
Xanthine 40; 0.107 (0.155) 39; −0.11 (0.163) 40; −0.092 (0.145) 39; −0.092 (0.169) 40; 0.278 (0.158) 39; −0.296 (0.135) −0.039 (0.03); 1.726; 0.
Xanthosine 40; 0.138 (0.153) 39; −0.141 (0.164) 40; 0.086 (0.166) 39; 0.023 (0.144) 40; 0.064 (0.177) 39; −0.155 (0.149) −0.003 (0.024); 0.018; 0







































Kortteenniemi et al. Peripheral Metabolic Changes of tDCSduring the 10-session intervention. Brunoni et al. (24–26)
investigated the effect of tDCS on circulating neurotrophins and
their receptors (brain-derived neurotrophic factor (BDNF),
neurotrophins 3 and 4 (NT-3 and NT-4), nerve growth factor,
glial cell line derived neurotrophic factor (GDNF), and soluble
tumour necrosis factor receptors 1 and 2), but found no difference
between individuals receiving tDCS vs. sham stimulation. A few
year later (27), the same group expanded their research to
interleukins and tumour necrosis factor alpha, and again
observed no differences observed between participants receiving
tDCS vs. sham stimulation. In contrast, in a study by Hadoush
et al. (28), belonging to the tDCS group vs. sham stimulation was
associated with an increase in serum BDNF levels in Parkinson’s
disease patients undergoing a 10-session tDCS intervention. The
effects of tDCS on the concentrations of soluble neuronal cell
adhesion molecules in minimally conscious subjects have also
been studied; the authors observed no significant tDCS-related
changes (29). Unfortunately, our metabolomics panel did not
include any of the aforementioned metabolites, which limits
comparisons with these previous observations. However, these
studies (with the exception of glucose studies) focused more on
larger molecules in peripheral blood in contrast to the small
metabolic products we measured.
Some earlier reports have suggested that tDCS may cause
intracerebral changes in the concentrations of certainFrontiers in Psychiatry | www.frontiersin.org 8metabolites. For example, Dickler et al. (30) found an increase
in dorsolateral prefrontal cortical GABA levels under the
stimulated area in patients with a gambling disorder, while
Hone-Blanchet et al. (31) recorded elevated striatal levels of N-
acetylaspartate and Glx (a combined measurement of glutamate
and glutamine), but no differences in the levels of GABA in
healthy subjects. Although a previous study (10) did claim that
tDCS-induced alterations in central metabolism are reflected in
the peripheral circulation, we observed no tDCS-related
alterations in the serum levels of N-acetylaspartate or GABA
among healthy individuals. Nevertheless, the possibility of such
alterations at the cerebral level cannot be ruled out; tDCS may
have induced central nervous system alterations that are not
reflected as meaningful alterations at the peripheral level.
The main strengths of our study are the relatively large sample
size (previous studies focusing on tDCS-induced possible
peripheral metabolic changes have utilised samples ranging from
14 to 60 individuals) (13, 32) and the implementation of a
randomized, double-blind, controlled study design. Furthermore,
in order to reduce potential confounding due to individual lifestyle
factors, we provided the study participants with detailed
instructions regarding lifestyle behaviours potentially modifying
the effects of tDCS before each tDCS/sham stimulation session. All
participants were instructed to fast before providing blood
samples. Controlling for these factors most likely contributed toFIGURE 3 | Power curves for the detection of “Time × Group” coefficient values. The current sample size per experimental group confers ≥80% power to detect
“Time Group” coefficients of ≥0.0976 (type-I error rate: 0.05) and ≥0.1493 (type-I error rate: 5.376 · 10−4).May 2020 | Volume 11 | Article 403
Kortteenniemi et al. Peripheral Metabolic Changes of tDCSthe more homogeneous findings between the two study groups,
whereas some previous studies have not reported whether they
provided similar instructions to their participants.
Some issues need to be taken into consideration while
interpreting the findings from our have received a similar
tDCS regime (i.e., a 20-minute stimulation session with a
current of 2 mA for five consecutive days). While the montage
we used is common in both clinical and experimental tDCS
studies, caution is advised when extrapolating our results to
other montages. The tDCS group had a BMI of 26, compared to
the BMI of 25.4 in the control group. While the difference
between these group means is statistically non-significant, it is
of note that a BMI of 26 is considered as overweight, and tDCS
has been demonstrated to have different effects in overweight
individuals compared to those of normal weight (decreased
systemic glucose uptake in response to tDCS in obese
individuals compared to normal weight individuals) (33). Thus
we cannot completely rule out BMI affecting the results.
In addition, due to the extensive number of comparisons and
the stringent alpha levels resulting from correction to the
number of these comparisons, we cannot rule out some real
effects erroneously appearing as non-significant. The study
protocol allowed a maximum time interval of 5 min betweenFrontiers in Psychiatry | www.frontiersin.org 9the end of stimulation and the venipuncture, but unfortunately
we did not use a timer to record this interval. In practice, the
circa 20-metre transfer from the stimulation room to the blood
sampling station, as well as preparations necessary for the blood
draw, were estimated to take approximately 3 min, leaving
approximately 2 min for individual variation in the interval.
Therefore, we cannot exclude potential random variation that
this time interval may have induced in our findings.
It is also important to note that any tDCS-related changes
may have a ceiling effect in the healthy brain. For example, a
greater improvement in cognitive task performance following
tDCS was observed in neuropsychiatric patients than in healthy
controls (34). Therefore, our observations may have been
different among, for example, patients with depression.
Nevertheless, we sought to provide a healthy male volunteer
‘baseline’ offindings that we hope both our group and others will
in the future be able to use as a healthy individual reference when
conducting further investigations among patients.
In the present investigation, both the participants and the
experimenters were able to distinguish sham and active
stimulation at the beginning of the protocol, which is in
contrast to some previous studies (35). This might be a result
of the different protocols applied here, with its higher currentsFIGURE 4 | Estimation of the number of participants per group required for the significant detection of “Time × Group” coefficients (type-I error rates: 0.05 and
5.576 · 10−4; minimum detection power: 80%) for each metabolite according to the coefficient values obtained in these study models. In the upper right corner, there
is a resized section of the overall curves clarifying the metabolites for which the estimated number of participants per group is ≤150.May 2020 | Volume 11 | Article 403
Kortteenniemi et al. Peripheral Metabolic Changes of tDCSand greater current density as compared to earlier investigations.
In addition, we also had larger study groups, resulting in a higher
power to detect smaller failures in blinding. However, this issue
should not have significantly impacted on our findings.
Our power calculations suggested that enormous sample sizes
would be necessary to detect any changes in most of the studied
compounds. However, while the power calculations indicated that
some of the metabolites would require sample sizes at the level of
thousands of individuals to be detected as statistically significant,
some metabolites, such as xanthine and hippuric acid, could be
detected as significant with group sizes of less than 100. These
power calculations may be beneficial when planning future
studies. Furthermore, GABA and glutamate, for which our
observations suggest sufficient power for detection with sample
sizes of 35 and 164 per group, respectively, are of special interest
for clinical tDCS research. Both GABAergic and glutaminergic
systems have been suggested to play a significant part in, for
example, the pathophysiology of depression (36), and any changes
in these markers may be of interest from the point of view of
treatment mechanisms or the prediction of treatment efficacy.CONCLUSIONS
We found that five daily sessions of tDCS, applied to healthy
male adults, did not result in significant changes in peripheral
blood metabolites. These results indicate that tDCS may be
metabolically safe, at least for healthy participants, but more
research is needed to determine whether the results would be the
same in populations with metabolic disturbances. Further studies
with larger samples as well as with female volunteers are also
warranted. Our power calculations offer a useful, evidence-based
baseline for designing such studies.DATA AVAILABILITY STATEMENT
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